0
0

Migraine – Epidemiology Forecast to 2030

Migraine is a common neurological disorder characterized by intense, debilitating headaches. It is characterized by a unilateral, pulsating, or throbbing pain that is moderate to severe and is aggravated by physical activity. According to the International Classification of Headache Disorders, Third Edition (ICHD-3) criteria, migraine is considered to be one of two types based on the presence of characteristic transient focal neurological symptoms that usually precede or sometimes accompany the headache: migraine with aura, and migraine without aura (Olesen, 2018). According to the frequency of headaches, migraine can be divided into episodic migraine with the primary criterion of less than 15 headache days per month and chronic migraine with 15 or more headache days per month (Buse et al., 2012; Olesen, 2018).

This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for migraine in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiology forecast for the 12-month total prevalent cases and 12-month diagnosed prevalent cases of migraine. The 12-month total prevalent cases and 12-month diagnosed prevalent cases of migraine are segmented by age (18 years and older), sex, subtype (migraine with aura and migraine without aura). The report also includes the 12-month total and 12-month diagnosed prevalent cases of migraine further segmented by migraine frequency into episodic migraine and chronic migraine for both sexes and ages 18 years and older. The following data describes epidemiology of migraine. In the 7MM, GlobalData epidemiologists forecast an increase in the 12-month total prevalent cases of migraine from 72,739,456 cases in 2020 to 73,708,346 cases in 2030, at an AGR of 0.13% over the forecast period. Women accounted for more 12-month total prevalent cases of migraine than men in the 7MM and it predominantly affects younger adults. These findings are in line with the GlobalData estimates and these trends are reflected in GlobalData’s forecast for the 12-month total prevalent cases for the 7MM.

Scope

The Migraine Epidemiology Report and Model provide an overview of the risk factors and global trends of Migraine in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

The report includes a 10-year epidemiological forecast for the 12-month total prevalent cases and 12-month diagnosed prevalent cases of migraine segmented by sex and age (ages ≥18 years). The 12-month total prevalent cases and 12-month diagnosed prevalent cases of migraine are further segmented by subtype (migraine with aura and migraine without aura). The report also includes the 12-month total and 12-month diagnosed prevalent cases of migraine further segmented by migraine frequency into episodic migraine and chronic migraine for both sexes and ages 18 years and older.

The migraine epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy

The Migraine Epidemiology series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global migraine market.

Quantify patient populations in the global migraine market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for migraine therapeutics in each of the markets covered.

Understand magnitude of migraine population by subtype, and migraine frequency.

Table of Contents

| About GlobalData

1 Migraine: Executive Summary

1.1 Catalyst

1.2 Related Reports

1.3 Upcoming Reports

2 Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global and Historical Trends

2.4 7MM Forecast Methodology

2.4.1 Sources

2.4.2 Forecast Assumptions and Methods

2.4.3 Forecast Assumptions and Methods: 12-Month Total Prevalent Cases of Migraine

2.4.4 Forecast Assumptions and Methods: 12-Month Total Prevalent Cases of Migraine by Frequency

2.4.5 12-Month Total Prevalent Cases of Migraine by Type

2.4.6 12-Month Diagnosed Prevalent Cases of Migraine

2.5 Epidemiological Forecast for Migraine (2020–2030)

2.5.1 12-Month Total Prevalent Cases of Migraine

2.5.2 Age-Specific 12-Month Total Prevalent Cases of Migraine

2.5.3 Sex-Specific 12-Month Total Prevalent Cases of Migraine

2.5.4 12-Month Total Prevalent Cases of Migraine by Frequency of Episodic and Chronic

2.5.5 12-Month Total Prevalent Cases of Migraine by Type

2.5.6 12-Month Diagnosed Prevalent Cases of Migraine

2.6 Discussion

2.6.1 Epidemiological Forecast Insight

2.6.2 COVID-19 Impact

2.6.3 Limitations of the Analysis

2.6.4 Strengths of the Analysis

3 Appendix

3.1 Bibliography

3.2 About the Authors

3.2.1 Epidemiologist

3.2.2 Reviewers

3.2.3 Global Director of Therapy Analysis and Epidemiology

3.2.4 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

List of Tables

Table 1: Summary of Newly Added Data Types

Table 2: Summary of Updated Data Types

Table 3: Risk Factors and Comorbidities for Migraine

List of Figures

Figure 1: 7MM, 12-Month Total Prevalent Cases of Migraine, Both Sexes, N, Ages ≥18 Years, 2020 and 2030

Figure 2: 7MM, 12-Month Diagnosed Prevalent Cases of Migraine, Both Sexes, N, Ages ≥18 Years, 2020 and 2030

Figure 3: 7MM, 12-Month Total Prevalence of Migraine, Men and Women, %, Ages ≥18 Years, 2020

Figure 4: 7MM, Sources Used and Not Used to Forecast the 12-Month Total Prevalent Cases of Migraine

Figure 5: 7MM, Sources Used to Forecast the 12-Month Total Prevalent Cases of Migraine by Frequency

Figure 6: 7MM, Sources Used to Forecast the 12-Month Total Prevalent Cases of Migraine by Type

Figure 7: 7MM, Sources Used to Forecast the Diagnosis Rate of Migraine

Figure 8: 7MM, 12-Month Total Prevalent Cases of Migraine, N, Both Sexes, Ages ≥18 Years, 2020

Figure 9: 7MM, 12-Month Total Prevalent Cases of Migraine by Age, N, Both Sexes, 2020

Figure 10: 7MM, 12-Month Total Prevalent Cases of Migraine by Sex, N, Ages ≥18 Years, 2020

Figure 11: 7MM, 12-Month Total Prevalent Cases of Migraine by Frequency, N, Both Sexes, Ages ≥18 Years, 2020

Figure 12: 7MM, 12-Month Total Prevalent Cases of Migraine by Type, N, Both Sexes, Ages ≥18 Years, 2020

Figure 13: 7MM, 12-Month Diagnosed Prevalent Cases of Migraine, N, Both Sexes, Ages ≥18 Years, 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports